Erythropoiesis-stimulating agents in kidney and cardiac disease.

For the last 20 years, erythropoiesis-stimulating agents have transformed the lives of renal dialysis patients, and they are now being used to correct anaemia in chronic kidney disease and after renal transplantation. In future, these drugs may be used outside the renal clinic to improve outcomes in patients with chronic heart failure.